Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. (Q51953367)

18 April 2018

title

Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. (English)

1 reference

18 April 2018

0 references

0 references

Xiang Yang Zhang

1

1 reference

18 April 2018

Dong Feng Zhou

2

1 reference

18 April 2018

Pei Yan Zhang

3

1 reference

18 April 2018

Gui Ying Wu

4

1 reference

18 April 2018

Lian Yuan Cao

5

1 reference

18 April 2018

Yu Cun Shen

6

1 reference

18 April 2018

language of work or name

English

0 references

publication date

1 October 2002

1 reference

18 April 2018

published in

Schizophrenia Research

1 reference

18 April 2018

volume

57

1 reference

18 April 2018

page(s)

247-258

1 reference

18 April 2018

issue

2-3

1 reference

18 April 2018

Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Serum cytokine concentrations in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Cytokine production in drug-free and neuroleptic-treated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Biological significance of soluble IL-2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Cytokine profiles in drug-naive schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Decreased interleukin-2 production in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Autoimmunity in schizophrenia: a review of recent findings

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Increased prevalence of antibrain antibodies in the sera from schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Biological and clinical aspects of interleukin 6.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Decreased interleukin-2 production in Korean schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Interleukin-6 and its receptor: a paradigm for cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Cytokines and the brain: implications for clinical psychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

A role for interleukin-2 in the regulation of striatal dopaminergic function

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

The effects of psychological stress on plasma interleukin-6 activity in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Neuropsychiatric aspects of cytokines research: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

The role of immune function in schizophrenia: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Elevated circulating levels of IL-6 in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

The role of chemokines in inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Serum interleukin-6 in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Elevated interleukin-6 in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Increase of plasma IL-6 concentration with age in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900296-1

7 January 2021

10.1016/S0920-9964(01)00296-1

Identifiers

DOI

1 reference

18 April 2018

PubMed ID

12223256

1 reference

18 April 2018